Market revenue in 2023 | USD 54.3 million |
Market revenue in 2030 | USD 187.1 million |
Growth rate | 19.3% (CAGR from 2023 to 2030) |
Largest segment | Gmp grade |
Fastest growing segment | GMP Grade |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | R&D Grade, GMP Grade |
Key market players worldwide | Charles River Laboratories International Inc, Danaher Corp, Kaneka Corp, Eurofins Scientific SE, Lonza Group Ltd, Akron Biotechnology, Luminous BioSciences, Lonza Group Ltd ADR, Cell & Gene Therapy, Nature Technology, VGXI |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Gmp grade was the largest segment with a revenue share of 86.19% in 2023. Horizon Databook has segmented the Brazil plasmid dna manufacturing market based on r&d grade, gmp grade covering the revenue growth of each sub-segment from 2018 to 2030.
Rise in government initiatives to improve the domestic drug manufacturing system and reduce the country’s pharma trade deficit is expected to positively impact market growth. For instance, in January 2022, the Latin American science institution, Brazil, received approval to domestically manufacture and develop AstraZeneca’s COVID-19 vaccine—Vaxzevria.
Fiocruz, a federal, public institution, would allocate the doses of Vaxzevria to the Brazilian Ministry of Health for its public use. Furthermore, the presence of several GMP-certified plants along with the low manufacturing costs are attracting manufacturers from other countries to establish their facilities in this country, thus driving growth.
The country is also one of the top vaccine producers in the region with a leading biological manufacturing infrastructure. Brazil is responsible for 54.2% of overall vaccine production globally. Hence, with advent of advanced mRNA- and DNA-based vaccines, the demand for plasmid DNA-based raw material is expected to grow in the coming years.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil plasmid dna manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Brazil plasmid dna manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account